WO2012137940A1 - Oil-in-water emulsion composition - Google Patents

Oil-in-water emulsion composition Download PDF

Info

Publication number
WO2012137940A1
WO2012137940A1 PCT/JP2012/059568 JP2012059568W WO2012137940A1 WO 2012137940 A1 WO2012137940 A1 WO 2012137940A1 JP 2012059568 W JP2012059568 W JP 2012059568W WO 2012137940 A1 WO2012137940 A1 WO 2012137940A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
emulsion composition
component
water emulsion
water
Prior art date
Application number
PCT/JP2012/059568
Other languages
French (fr)
Japanese (ja)
Inventor
武司 村田
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 花王株式会社 filed Critical 花王株式会社
Publication of WO2012137940A1 publication Critical patent/WO2012137940A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • A61K8/375Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/06Emulsions
    • A61K8/062Oil-in-water emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26Aluminium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to an oil-in-water emulsion composition containing rhododendrol and / or a derivative thereof.
  • rhododendrol and its derivatives are known as ingredients for preventing and improving skin pigmentation such as spots and freckles (see Patent Documents 1 to 3). It has been pointed out that these rhododendrol or derivatives thereof are amphiphilic substances having low solubility in both aqueous bases and oil bases. For this reason, when the emulsion composition is used, rhododendrol or a derivative thereof tends to collect near the interface of the emulsified particles and easily precipitate, so that there is a problem that problems are likely to occur in stability and usability.
  • An object of the present invention is to provide an oil-in-water emulsion composition
  • an oil-in-water emulsion composition comprising the following components (A) to (C).
  • (A) Rhodendrol or a derivative thereof represented by the following general formula (1)
  • R 1 represents a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.
  • B Propylene glycol mono C 10 -C 26 fatty acid ester
  • C Water-swellable clay mineral
  • the present invention also relates to a method for improving the low temperature stability of an oil-in-water emulsion composition comprising the component (B) and the component (C) in the oil-in-water emulsion composition containing the component (A). Is to provide.
  • the present invention relates to an oil-in-water emulsion composition containing rhododendrol or a derivative thereof, having good low-temperature stability, high skin safety, and excellent whitening effect and feeling of use.
  • the oil-in-water emulsion composition of the present invention contains rhododendrol or a derivative thereof having a melanin production inhibitory effect in a sufficient amount, but has excellent low-temperature stability, high skin safety, whitening effect, It has excellent usability.
  • Rhododendrol or a derivative thereof used in the present invention is represented by the following general formula (1).
  • R 1 represents a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.
  • Lod Den Dror R 1 is a hydrogen atom [4-(p-hydroxyphenyl) -2-butanol] is a known compound, Acer Maximowiczianum (Acer nikoence Maxim.) It is known that they are included in As the rhododendrol, one synthesized by a conventionally known method may be used, or a megsurinoki extract may be used.
  • a rhododendrol derivative (hereinafter also referred to as acylated rhododendrol) in which R 1 is an acyl group having 2 to 20 carbon atoms is a known compound such as acylation of a phenol compound.
  • R 1 is an acyl group having 2 to 20 carbon atoms
  • acylated rhododendrol a known compound such as acylation of a phenol compound.
  • a saturated or unsaturated aliphatic acyl group is preferable, and an alkanoyl group is more preferable.
  • Specific examples include an acetyl group, a propionyl group, a butyroyl group, an isobutyroyl group, a valeryl group, a hexanoyl group, an octanoyl group, a lauroyl group, a palmitoyl group, and a stearoyl group.
  • an alkanoyl group having 2 to 18 carbon atoms is preferable, an alkanoyl group having 2 to 8 carbon atoms is more preferable, and an alkanoyl group having 2 to 4 carbon atoms is preferable.
  • the group is more preferable, and specific examples of the more preferable acyl group include an acetyl group, a propionyl group, a butyroyl group, and an isobutyroyl group.
  • acylated rhododendrol in the component (A) of the present invention include acetyl rhododendrol, butyroyl rhododendrol, hexanoyl rhododendrol, octanoyl rhododendrol, dodecanoyl rhododendrol, tetradecadolol.
  • Examples include noyl rhododendrol, hexadecanoyl rhododendrol, and octadecanoyl rhododendrol.
  • a rhododendrol derivative (hereinafter also referred to as rhododendrol glycoside) in which R 1 is a sugar residue of a monosaccharide or a disaccharide is a known method (US Patent No. 1). 3201385).
  • rhododendrol glycoside in which R 1 is a sugar residue of a monosaccharide or a disaccharide is a known method (US Patent No. 1). 3201385).
  • the desired glycoside is eliminated by eliminating the acetyl group in the presence of alkali. Can be easily obtained as white powder crystals. It can also be obtained by reducing raspberry ketone glycosides. It is also possible to isolate from natural products.
  • the sugar residue is a reducing monosaccharide or disaccharide, and specific examples include monosaccharides such as glucose, galactose, xylose, mannose, N-acetylglucosamine, and disaccharides such as maltose, cellobiose, and gentibiose. Can do.
  • monosaccharides such as glucose, galactose, xylose, mannose, N-acetylglucosamine
  • disaccharides such as maltose, cellobiose, and gentibiose.
  • isomers having an ⁇ bond and a ⁇ bond there are isomers having an ⁇ bond and a ⁇ bond, and a single or a mixture thereof can also be used.
  • rhododendrol glycosides in the component (A) of the present invention include rhododendrol-D-glucoside ( ⁇ or ⁇ form), rhododendrol-D-galactoside ( ⁇ or ⁇ form), rhododendrol. -D-xyloside ( ⁇ or ⁇ form), rhododendrol-D-maltoside ( ⁇ or ⁇ form) and the like can be mentioned.
  • the component (A) of the present invention has an optical isomer, but the (+) isomer, the ( ⁇ ) isomer alone, or a mixture ( ⁇ ) thereof can also be used.
  • the content of the component (A) in the composition of the present invention is preferably 0.5 to 20% by mass from the viewpoint of obtaining a sufficient effect as a melanin production inhibitor, skin irritation and low temperature stability.
  • the content is 0.5 to 15% by mass, and more preferably 0.5 to 10% by mass.
  • the content in the composition is preferably 0 because the melanin production inhibitory effect is high.
  • the content in the composition is preferably 0.5 to 20% by mass, more preferably 0.5 to 15% by mass, and still more preferably 0.5 to 10% by mass.
  • the (B) propylene glycol monofatty acid ester used in the present invention is a monofatty acid ester having 10 to 26 carbon atoms of fatty acid from the viewpoint of low-temperature stability and feeling of use of rhododendrol or a derivative thereof. Even when a difatty acid ester of propylene glycol or a mono-C 8 fatty acid ester of propylene glycol is blended, an oil-in-water emulsion composition having good stability cannot be obtained.
  • the (B) propylene glycol mono C 10 -C 26 fatty acid ester those represented by the following general formula (2) are preferable.
  • R 2 represents a linear or branched, saturated or unsaturated aliphatic hydrocarbon group having 9 to 25 carbon atoms.
  • the more preferable component (B) used in the present invention a low temperature in view of stability and usability, a straight chain or branched chain of R 2 is a carbon number of 11-23, saturated or unsaturated aliphatic
  • hydrocarbon groups include propylene glycol laurate, propylene glycol myristate, propylene glycol palmitate, propylene glycol stearate, propylene glycol isostearate, propylene glycol oleate, propylene glycol linoleate, linolenic acid
  • Examples include propylene glycol, propylene glycol palmitooleate, and propylene glycol behenate.
  • these 1 type (s) or 2 or more types can be combined suitably and can be used suitably.
  • (B) component used by this invention is a well-known substance, for example, can manufacture easily by esterification of a fatty acid and propylene glycol.
  • it is also commercially available, and as propylene glycol laurate, Sunsoft 25BD sold by Taiyo Kagaku Co., Ltd., as propylene glycol isostearate, cislol PGMIS, propylene glycol oleate sold by Croda.
  • Sunsoft 25 ODV sold by Taiyo Kagaku Co., Ltd. and propylene glycol behenate include Schercemol PGML Ester sold by Novenon.
  • the content of the component (B) in the composition of the present invention is preferably 0.05 to 30% by mass, more preferably 0.05 to 20% from the viewpoints of low-temperature stability, usability, and skin irritation.
  • the mass is more preferably 0.05 to 15 mass%, still more preferably 0.1 to 10 mass%.
  • the content mass ratio (A / B) of the component (A) and the component (B) of the present invention is preferably 0.1 to 10 from the viewpoint of feeling of use (no stickiness, familiar skin) and skin irritation. More preferably, it is from 0.1 to 5, more preferably from 0.2 to 5, even more preferably from 0.2 to 3, and even more preferably from 0.5 to 5.
  • the (C) water-swellable clay mineral used in the present invention is a clay mineral that swells when mixed with water to form a gel, and may be any clay mineral that can be blended in an external preparation for skin, montmorillonite, Smectite clay minerals such as beidellite, nontronite, saponite, hectorite, sauconite, stevensite, clay minerals such as talc and mica, layered silicates such as disilicate, Eilerite, macatite, magadiite, and Kenyaite. These may be used singly or in combination of two or more. These water-swellable clay minerals are preferably used in the form of a dispersion (for example, sol or gel) or a suspension.
  • a dispersion for example, sol or gel
  • a suspension for example, sol or gel
  • smectite clay minerals are preferred, and those having alkali metal or alkaline earth metal ions in the crystal lattice structure can be mentioned.
  • hectorite montmorillonite, nontronite, saponite, beidellite, soconite, and mixtures thereof, and particularly preferred are hectorite, montmorillonite, saponite, and mixtures thereof.
  • These components (C) are generally commercially available, and products containing montmorillonite include Kunipia G, Kunipia F (manufactured by Kunimine Industries), Bentonite W, Bengel (manufactured by Hojun Co.); Veegum T, Veegum HV, Veegum F, Veegum K (manufactured by Vanderbilt); as products containing hectorite, Benton EW, Benton LT (manufactured by Elementis Japan), Hectablite AW, Hectablite 200, Hectablite EW (manufactured by American Colloid) and the like can be mentioned.
  • the content of the component (C) in the composition of the present invention is 0.01 to 10% by mass, more preferably 0.02 to 5% by mass, and still more preferably, from the viewpoint of low-temperature stability, usability, and skin irritation. Is from 0.05 to 5% by weight, even more preferably from 0.05 to 2% by weight, and most preferably from 0.1 to 3% by weight.
  • the content ratio (B / C) of the component (B) and the component (C) of the present invention is preferably 0.03 to 35 from the viewpoints of stability, feeling of use (stickiness, familiarity with skin) and skin irritation. More preferably, it is 0.4 to 35, more preferably 0.5 to 15, more preferably 0.5 to 10, still more preferably 0.5 to 8, and further preferably 1 to 5. is there.
  • (D) monohydric to trihydric alcohol in order to adjust the feeling of use, (D) monohydric to trihydric alcohol can be further contained.
  • the component (D) include monohydric alcohols such as ethanol, propanol, isopropanol, butyl alcohol and the like, and monovalent alcohols such as ethanol, propanol, isopropanol, and butyl alcohol.
  • Divalent alcohols include propylene glycol, 1, Examples of the dihydric alcohol having 2 to 6 carbon atoms such as 2-pentanediol, 1,3-butylene glycol, dipropylene glycol and the like, and examples of the trivalent alcohol include 3 to 6 carbon atoms such as glycerin and isoprene glycol.
  • monohydric alcohols in the present invention, one or more selected from these monovalent to trivalent alcohols can be used in appropriate combination.
  • one or more selected from the group consisting of ethanol, dipropylene glycol, 1,3-butylene glycol and glycerin can be preferably used.
  • the oil-in-water emulsion composition contains about 10% by mass of component (D).
  • the content of the component (D) in the composition of the present invention can be 10% by mass or less from the viewpoints of skin irritation mitigation and feeling of use (tackiness, familiarity with skin). Is preferably 10 to 10% by mass, more preferably 0.1 to 8% by mass, and still more preferably 0.5 to 6% by mass.
  • oil-in-water emulsion composition of the present invention in addition to the above essential components, other components usually blended in pharmaceuticals, quasi-drugs, cosmetics and the like, for example, oil agents, within the range not impairing the effects of the present invention.
  • Oil agents within the range not impairing the effects of the present invention.
  • Moisturizers, thickeners, preservatives, pH adjusters, water, alcohols, drugs, ultraviolet absorbers, ultraviolet scattering agents, dyes, fragrances, and the like can be appropriately blended as necessary.
  • the use of the oil-in-water emulsion composition of the present invention is arbitrary, it can be suitably used for cosmetics, pharmaceuticals, quasi drugs and the like.
  • skin cosmetics such as lotions, milky lotions, beauty creams, base cosmetics, sunscreen cosmetics, packs, massage cosmetics, etc .; can be suitably used as external medicines such as creams containing various drugs.
  • the oil-in-water emulsion composition of the present invention does not have a sticky feeling or a slimy feeling, and therefore can be suitably used as a skin cosmetic.
  • the dosage form of the oil-in-water emulsion composition of the present invention is arbitrary and is prepared as a liquid, emulsion, gel, spray, mousse or the like.
  • An oil-in-water emulsion composition comprising the following components (A) to (C): (A) Rhodendrol or a derivative thereof represented by the following general formula (1)
  • R 1 represents a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.
  • B Propylene glycol mono C 10 -C 26 fatty acid ester
  • C Water-swellable clay mineral ⁇ 2>
  • R 1 in the general formula (1) is a hydrogen atom, a saturated or unsaturated fat having 2 to 20 carbon atoms ⁇ 1> in water, which is a group acyl group, or a sugar residue of a monosaccharide or a disaccharide, preferably a hydrogen atom, an alkanoyl group having 2 to 18 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.
  • Oil-type emulsion composition is preferably a hydrogen atom, an alkanoyl group having 2 to 8 carbon atoms, or a sugar residue of glucose, galactose, xylose, mannose, N-acetylglucosamine, maltose, cellobiose or gentaviose.
  • R 1 in the general formula (1) is preferably a hydrogen atom, an alkanoyl group having 2 to 8 carbon atoms, or a sugar residue of glucose, galactose, xylose, mannose, N-acetylglucosamine, maltose, cellobiose or gentaviose.
  • ⁇ 1> or ⁇ 2> of the oil-in-water type more preferably a hydrogen atom, an alkanoyl group having 2 to 4 carbon atoms, or a sugar residue of glucose, galactose, xylose, mannose, N-acetylglucosamine Emulsified composition.
  • the content of the component (A) is 0.5 to 20% by mass, preferably 0.5 to 15% by mass, more preferably 0.5 to 10% by mass, and further preferably 0.5 to 5% by mass.
  • the component (B) is represented by the general formula (2)
  • R 2 represents a linear or branched, saturated or unsaturated aliphatic hydrocarbon group having 9 to 25 carbon atoms.
  • Component (B) is propylene glycol laurate, propylene glycol myristate, propylene glycol palmitate, propylene glycol stearate, propylene glycol isostearate, propylene glycol oleate, propylene glycol linoleate, propylene glycol linolenate, palmitate
  • the oil-in-water emulsion composition according to any one of ⁇ 1> to ⁇ 6>, wherein the emulsion composition is one or more selected from the group consisting of propylene glycol tooleate and propylene glycol behenate.
  • the content of the component (B) is 0.05 to 30% by mass, preferably 0.05 to 20% by mass, more preferably 0.05 to 15% by mass, and further preferably 0.1 to 10% by mass. %, More preferably 0.1 to 5% by mass, the oil-in-water emulsion composition according to any one of ⁇ 1> to ⁇ 7>.
  • the mass ratio (A / B) of the component (A) to the component (B) is 0.1 to 10, preferably 0.1 to 5, more preferably 0.2 to 5, and still more preferably 0.8.
  • the oil-in-water emulsion composition according to any one of ⁇ 1> to ⁇ 8> which is 2 to 3, more preferably 0.5 to 5.
  • Component (C) is at least one selected from hectorite, montmorillonite, nontronite, saponite, beidellite and soconite, preferably at least one selected from hectorite, montmorillonite and saponite ⁇ 1
  • the content of ⁇ 11> component (C) is 0.01 to 10% by mass, preferably 0.02 to 5% by mass, more preferably 0.05 to 5% by mass, and still more preferably 0.05 to 2% by mass. %, More preferably 0.1 to 3% by mass, the oil-in-water emulsion composition according to any one of ⁇ 1> to ⁇ 10>.
  • the mass ratio (B / C) of the component (B) to the component (C) is 0.03 to 35, preferably 0.4 to 35, more preferably 0.5 to 15, and still more preferably 0.
  • Oil-in-water emulsion compositions were prepared according to the formulations shown in Table 1-1, 1-2, and Table 2, and the evaluation test was performed. The results are shown in Tables 1-1, 1-2, and Table 2.
  • B Components 10 to 13 and 21 to 22 are mixed, heated to 80 ° C., and mixed with stirring.
  • D After cooling, component 14 is added to C, and further stirred and mixed.
  • Comparative Example 1 containing no component (B) could not maintain room temperature and low temperature stability.
  • Comparative Examples 2 and 5 using propylene glycol caprylate having less than 9 carbon atoms instead of component, and Comparative Examples 3 and 6 using propylene glycol dicaprylate that is not a mono-body are also sufficient in room temperature and low temperature stability.
  • Comparative Examples 4, 7, and 8 containing no component (C) no precipitation was observed, but it was not satisfactory in terms of use such as non-stickiness, moist feeling, and good skin familiarity.
  • the Example of this invention it was excellent in normal temperature and low temperature stability. Since no precipitation occurs, it is expected that a high whitening effect can be obtained even if the amount of component (A) is small.
  • the skin irritation and the feeling in use were evaluated well by using the components (A) to (C) in combination.
  • formulation examples of the oil-in-water emulsion composition of the present invention will be shown. All are expected to have excellent low-temperature stability, high skin safety, and excellent whitening effect and feeling of use.
  • Formulation example 2 (milky lotion) Ingredient Mass% Rhododendrol 1.0 Butyroyl rhododendrol 1.0 Propylene glycol isostearate (trade name: Cisrol PGMIS: manufactured by Croda) 1.0 Montmorillonite 0.4 Dipropylene glycol 3.5 Xanthan gum 0.05 Dimethicone 1.0 1.3-Butylene glycol 3.0 Stearic acid 0.4 Glycerol monostearate 1.2 Behenyl alcohol 0.1 Cholesterol 0.3 Olefin oligomer 8.0 N-stearoyl-L-glutamate sodium 0.5 Soymilk fermentation broth (trade name: Soymilk fermentation broth manufactured by Sansho Pharmaceutical Co., Ltd.) 0.1 Dutch mustard extract 0.1 (Product name: WaterCress-KB made by Silab) Ghetto leaf extract 0.1 (Product name: Moon peach leaf extract BG manufactured by Maruzen Pharmaceutical Co., Ltd.) Seaweed extract (trade name: Seaweed Extract M, manufactured by Maruzen Pharmaceutical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

Provided is an oil-in-water emulsified cosmetic containing rhododendrol or a derivative thereof, and having high low-temperature stability, high skin safety, and an excellent feeling upon use thereof. This oil-in-water emulsified cosmetic is characterized by containing the following components (A-C): (A) rhododendrol or a derivative thereof represented by general formula (1) (in the formula, R1 represents a hydrogen atom, a C2-20 acyl group, or a sugar moiety of a monosaccharide or a disaccharide); (B) a propylene glycol mono- C10-C26 fatty acid ester; and (C) a water-swellable clay mineral.

Description

水中油型乳化組成物Oil-in-water emulsion composition
 本発明はロドデンドロール及び/又はその誘導体を含有する水中油型乳化組成物に関する。 The present invention relates to an oil-in-water emulsion composition containing rhododendrol and / or a derivative thereof.
 従来、しみ、そばかす等の皮膚の色素沈着を予防、改善させる成分として、ロドデンドロール及びその誘導体が知られている(特許文献1~3参照)。これらロドデンドロール又はその誘導体は、水性基剤、油性基剤のいずれへも溶解性が低い両親媒性物質であることが指摘されている。そのため、乳化組成物にした場合には、乳化粒子の界面付近にロドデンドロール又はその誘導体が集まり、析出しやすいため、安定性、使用感において問題が生じやすいという課題があった。 Conventionally, rhododendrol and its derivatives are known as ingredients for preventing and improving skin pigmentation such as spots and freckles (see Patent Documents 1 to 3). It has been pointed out that these rhododendrol or derivatives thereof are amphiphilic substances having low solubility in both aqueous bases and oil bases. For this reason, when the emulsion composition is used, rhododendrol or a derivative thereof tends to collect near the interface of the emulsified particles and easily precipitate, so that there is a problem that problems are likely to occur in stability and usability.
 かかる課題を解決するため、例えば、ロドデンドロール及びその誘導体と、両親媒性高分子とを併用することで、高温条件下、光照射条件下において、変色や変臭を生ずる問題を改善することが提案されている(特許文献4参照)。 In order to solve such problems, for example, by using rhododendrol and its derivatives together with an amphiphilic polymer, the problem of causing discoloration and odor change under high temperature conditions and light irradiation conditions is improved. Has been proposed (see Patent Document 4).
 一方、グルセオフルビン、トルナフテート等の水に難溶性の物質と水膨潤性粘土鉱物とを併用することで、これら水に難溶性の物質の溶解度を改善することが提案されている(特許文献5参照)。 On the other hand, it has been proposed to improve the solubility of these water-insoluble substances by using a water-insoluble substance and water-swellable clay mineral together with water such as griseofulvin and tolnaftate (see Patent Document 5). .
特許第3340928号公報Japanese Patent No. 3340928 特許第3340935号公報Japanese Patent No. 3340935 特許第3455406号公報Japanese Patent No. 3455406 特開2008-081491号公報JP 2008-081491 A 特開平1-93541号公報JP-A-1-93541
 本発明は、下記成分(A)~(C)を含有することを特徴とする水中油型乳化組成物を提供することにある。
(A)下記一般式(1)で示されるロドデンドロール又はその誘導体
An object of the present invention is to provide an oil-in-water emulsion composition comprising the following components (A) to (C).
(A) Rhodendrol or a derivative thereof represented by the following general formula (1)
Figure JPOXMLDOC01-appb-C000003
Figure JPOXMLDOC01-appb-C000003
(式中、R1は、水素原子、炭素数2~20のアシル基、又は単糖類若しくは二糖類の糖残基を示す。)
(B)プロピレングリコールモノC10~C26脂肪酸エステル
(C)水膨潤性粘土鉱物
(In the formula, R 1 represents a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.)
(B) Propylene glycol mono C 10 -C 26 fatty acid ester (C) Water-swellable clay mineral
 また、本発明は、前記成分(A)を含有する水中油型乳化組成物において、前記成分(B)及び成分(C)を含有させることによる水中油型乳化組成物の低温安定性の改善方法を提供するものである。 The present invention also relates to a method for improving the low temperature stability of an oil-in-water emulsion composition comprising the component (B) and the component (C) in the oil-in-water emulsion composition containing the component (A). Is to provide.
発明の詳細な説明Detailed Description of the Invention
 ロドデンドロール又はその誘導体を含有する特許文献4記載の皮膚外用剤は、高温条件下や光照射条件下では安定であるが、使用感を考慮してロドデンドロール又はその誘導体を水中油型乳化組成物の形態とし、これを低温条件下で保存したところ、結晶が析出するという新たな問題が生じることが判明した。また、かかる皮膚外用剤において、ロドデンドロール又はその誘導体を含有する水中油型乳化組成物の安定性を保つためには、エタノール、1,3-ブチレングリコール、グリセリン等のアルコール類を高濃度併用する必要があることが分かり、皮膚刺激性が感じられる、感触調整が限定されてしまうという問題も生じることが判明した。
 従って、本発明は、ロドデンドロール又はその誘導体を含有し、低温安定性が良好で、皮膚安全性が高く、美白効果、使用感の優れた水中油型乳化組成物に関する。
The external preparation for skin described in Patent Document 4 containing rhododendrol or a derivative thereof is stable under high temperature conditions or light irradiation conditions. However, rhododendrol or a derivative thereof is emulsified in an oil-in-water emulsion in consideration of the feeling of use. When it was made into the composition form and this was preserve | saved under low-temperature conditions, it turned out that the new problem that a crystal | crystallization precipitates arises. In addition, in such an external preparation for skin, in order to maintain the stability of the oil-in-water emulsion composition containing rhododendrol or a derivative thereof, alcohols such as ethanol, 1,3-butylene glycol and glycerin are used in high concentration It has been found that there is a problem that skin irritation can be felt, and touch adjustment is limited.
Therefore, the present invention relates to an oil-in-water emulsion composition containing rhododendrol or a derivative thereof, having good low-temperature stability, high skin safety, and excellent whitening effect and feeling of use.
 そこで本発明者は、前記課題を解決すべく検討した。特許文献5に記載のようにロドデンドロール又はその誘導体に水膨潤性粘土鉱物を配合したところ、その溶解性を改善することができなかった。そこでさらに検討したところ、ロドデンドロール又はその誘導体と、プロピレングリコールの特定の範囲の炭素数のモノ脂肪酸エステルと、水膨潤性粘土鉱物とを併用することにより、水中においてコンプレックスを形成し、低温安定性が著しく向上すると共に、さらに優れた刺激緩和効果を有し、使用感の良い水中油型組成物が得られることを見出し、本発明を完成させるに至った。 Therefore, the present inventor studied to solve the above problems. When a water-swellable clay mineral was blended with rhododendrol or a derivative thereof as described in Patent Document 5, the solubility could not be improved. Therefore, when further examination was made, a complex was formed in water by using rhododendrol or a derivative thereof, a monofatty acid ester having a specific number of carbon atoms in propylene glycol, and a water-swelling clay mineral, and stable at low temperatures. As a result, the present inventors have found that an oil-in-water composition having an excellent stimulus relaxation effect and a good feeling of use can be obtained.
 本発明の水中油型乳化組成物は、メラニン生成抑制効果を有するロドデンドロール又はその誘導体を十分に効果を奏する量含有しながらも、低温安定性に優れ、皮膚安全性が高く、美白効果・使用感に優れたものである。 The oil-in-water emulsion composition of the present invention contains rhododendrol or a derivative thereof having a melanin production inhibitory effect in a sufficient amount, but has excellent low-temperature stability, high skin safety, whitening effect, It has excellent usability.
 以下、本発明の実施形態について詳述する。 Hereinafter, embodiments of the present invention will be described in detail.
 本発明に用いられる(A)ロドデンドロール又はその誘導体は、下記一般式(1)で表されるものである。 (A) Rhododendrol or a derivative thereof used in the present invention is represented by the following general formula (1).
Figure JPOXMLDOC01-appb-C000004
Figure JPOXMLDOC01-appb-C000004
(式中、R1は、水素原子、炭素数2~20のアシル基、又は単糖類若しくは二糖類の糖残基を示す。) (In the formula, R 1 represents a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.)
 本発明に用いられる(A)成分において、R1が水素原子であるロドデンドロール[4-(p-ヒドロキシフェニル)-2-ブタノール]は、公知の化合物であり、メグスリノキ(Acer nikoence Maxim.)等に含まれていることが知られている。ロドデンドロールは、従来公知の方法により合成されたものを用いてもよく、メグスリノキ抽出物を用いてもよい。 In component (A) used in the present invention, Lod Den Dror R 1 is a hydrogen atom [4-(p-hydroxyphenyl) -2-butanol] is a known compound, Acer Maximowiczianum (Acer nikoence Maxim.) It is known that they are included in As the rhododendrol, one synthesized by a conventionally known method may be used, or a megsurinoki extract may be used.
 本発明の(A)成分において、R1が炭素数2~20のアシル基であるロドデンドロール誘導体(以下、アシル化ロドデンドロールとも記載する。)は、フェノール化合物のアシル化などの公知の方法を用いて合成することができる。例えば、ピリジン中において4-(p-ヒドロキシフェニル)-2-ブタノンと脂肪酸クロライドとを反応させ、その後、水素化ホウ素ナトリウムで、ケトン基を還元することにより容易に得ることができる。R1のアシル基は飽和であっても不飽和であってもよく、又はアミノ基等の官能基を有するものであってもよい。このうち、飽和又は不飽和の脂肪族アシル基が好ましく、アルカノイル基がより好ましい。具体的には、アセチル基、プロピオニル基、ブチロイル基、イソブチロイル基、バレリル基、ヘキサノイル基、オクタノイル基、ラウロイル基、パルミトイル基、ステアロイル基等が挙げられる。このうち、水中油型乳化組成物への応用のしやすさの点から、炭素数2~18のアルカノイル基が好ましく、炭素数2~8のアルカノイル基がより好ましく、炭素数2~4のアルカノイル基がさらに好ましく、さらに好ましいアシル基の具体例としてアセチル基、プロピオニル基、ブチロイル基、イソブチロイル基等が挙げられる。 In the component (A) of the present invention, a rhododendrol derivative (hereinafter also referred to as acylated rhododendrol) in which R 1 is an acyl group having 2 to 20 carbon atoms is a known compound such as acylation of a phenol compound. Can be synthesized using methods. For example, it can be easily obtained by reacting 4- (p-hydroxyphenyl) -2-butanone with fatty acid chloride in pyridine and then reducing the ketone group with sodium borohydride. The acyl group of R 1 may be saturated or unsaturated, or may have a functional group such as an amino group. Among these, a saturated or unsaturated aliphatic acyl group is preferable, and an alkanoyl group is more preferable. Specific examples include an acetyl group, a propionyl group, a butyroyl group, an isobutyroyl group, a valeryl group, a hexanoyl group, an octanoyl group, a lauroyl group, a palmitoyl group, and a stearoyl group. Among these, from the viewpoint of easy application to an oil-in-water emulsion composition, an alkanoyl group having 2 to 18 carbon atoms is preferable, an alkanoyl group having 2 to 8 carbon atoms is more preferable, and an alkanoyl group having 2 to 4 carbon atoms is preferable. The group is more preferable, and specific examples of the more preferable acyl group include an acetyl group, a propionyl group, a butyroyl group, and an isobutyroyl group.
 本発明の(A)成分における具体的なアシル化ロドデンドロールとしては、アセチルロドデンドロール、ブチロイルロドデンドロール、ヘキサノイルロドデンドロール、オクタノイルロドデンドロール、ドデカノイルロドデンドロール、テトラデカノイルロドデンドロール、ヘキサデカノイルロドデンドロール、オクタデカノイルロドデンドロール等を挙げることができる。 Specific examples of the acylated rhododendrol in the component (A) of the present invention include acetyl rhododendrol, butyroyl rhododendrol, hexanoyl rhododendrol, octanoyl rhododendrol, dodecanoyl rhododendrol, tetradecadolol. Examples include noyl rhododendrol, hexadecanoyl rhododendrol, and octadecanoyl rhododendrol.
 本発明の(A)成分において、R1が単糖類又は二糖類の糖残基であるロドデンドロール誘導体(以下、ロドデンドロール配糖体とも記載する。)は、公知の方法(アメリカ特許第3201385号)を用いて得ることができる。例えば、トルエン等の有機溶媒中においてロドデンドロールとアセチル化糖を三フッ素化ホウ素やオキシ塩化リン等を触媒として縮合した後、アルカリ存在下にアセチル基を脱離することにより目的の配糖体を白色の粉末結晶として容易に得ることができる。また、ラズベリーケトングリコシドを還元することによっても得ることもできる。さらに、天然物から単離することも可能である。 In the component (A) of the present invention, a rhododendrol derivative (hereinafter also referred to as rhododendrol glycoside) in which R 1 is a sugar residue of a monosaccharide or a disaccharide is a known method (US Patent No. 1). 3201385). For example, after condensing rhododendrol and acetylated sugar in an organic solvent such as toluene using boron trifluoride or phosphorus oxychloride as a catalyst, the desired glycoside is eliminated by eliminating the acetyl group in the presence of alkali. Can be easily obtained as white powder crystals. It can also be obtained by reducing raspberry ketone glycosides. It is also possible to isolate from natural products.
 前記糖残基は、還元性の単糖類又は二糖類であり、具体的にはグルコース、ガラクトース、キシロース、マンノース、N-アセチルグルコサミン等の単糖類、マルトース、セロビオース、ゲンチビオース等の二糖類を挙げることができる。本発明の配糖体にはα結合及びβ結合を有する異性体が存在するが、単独またそれらの混合物を用いることもできる。 The sugar residue is a reducing monosaccharide or disaccharide, and specific examples include monosaccharides such as glucose, galactose, xylose, mannose, N-acetylglucosamine, and disaccharides such as maltose, cellobiose, and gentibiose. Can do. In the glycoside of the present invention, there are isomers having an α bond and a β bond, and a single or a mixture thereof can also be used.
 本発明の(A)成分における具体的なロドデンドロール配糖体は、ロドデンドロール-D-グルコシド(α又はβ体)、ロドデンドロール-D-ガラクトシド(α又はβ体)、ロドデンドロール-D-キシロシド(α又はβ体)、ロドデンドロール-D-マルトシド(α又はβ体)等を挙げることができる。 Specific rhododendrol glycosides in the component (A) of the present invention include rhododendrol-D-glucoside (α or β form), rhododendrol-D-galactoside (α or β form), rhododendrol. -D-xyloside (α or β form), rhododendrol-D-maltoside (α or β form) and the like can be mentioned.
 本発明の(A)成分には、光学異性体が存在するが、(+)体、(-)体単独でも、またそれらの混合物(±)を用いることもできる。 The component (A) of the present invention has an optical isomer, but the (+) isomer, the (−) isomer alone, or a mixture (±) thereof can also be used.
 (A)成分の本発明の組成物中における含有量は、メラニン生成抑制剤として十分な効果を得る点、皮膚刺激性及び低温安定性の点から、0.5~20質量%が好ましく、より好ましくは0.5~15質量%であり、さらに好ましくは0.5~10質量%である。特に、R1が、水素原子又は炭素数2~20のアシル基であるロドデンドロール又はその誘導体を用いる場合、メラニン生成抑制効果が高いことから、組成物中の含有量としては、好ましくは0.5~10質量%、より好ましくは0.5~5質量%、さらに好ましくは0.5~3質量%であり、R1が、単糖類又は二糖類の糖残基であるロドデンドロール誘導体を用いる場合、組成物中の含有量としては、好ましくは0.5~20質量%、より好ましくは0.5~15質量%、さらに好ましくは0.5~10質量%である。 The content of the component (A) in the composition of the present invention is preferably 0.5 to 20% by mass from the viewpoint of obtaining a sufficient effect as a melanin production inhibitor, skin irritation and low temperature stability. Preferably, the content is 0.5 to 15% by mass, and more preferably 0.5 to 10% by mass. In particular, when rhododendrol or a derivative thereof in which R 1 is a hydrogen atom or an acyl group having 2 to 20 carbon atoms is used, the content in the composition is preferably 0 because the melanin production inhibitory effect is high. A rhododendrol derivative having a content of 5 to 10% by mass, more preferably 0.5 to 5% by mass, and still more preferably 0.5 to 3% by mass, and R 1 is a sugar residue of a monosaccharide or disaccharide When is used, the content in the composition is preferably 0.5 to 20% by mass, more preferably 0.5 to 15% by mass, and still more preferably 0.5 to 10% by mass.
 本発明に用いられる(B)プロピレングリコールモノ脂肪酸エステルは、ロドデンドロール又はその誘導体の低温安定性及び使用感の点から、脂肪酸の炭素数が10~26であり、モノ脂肪酸エステルである。プロピレングリコールのジ脂肪酸エステルやプロピレングリコールのモノC8脂肪酸エステルを配合しても安定性の良好な水中油型乳化組成物は得られない。当該(B)プロピレングリコールモノC10~C26脂肪酸エステルとしては、下記一般式(2)で示されるものが好ましい。 The (B) propylene glycol monofatty acid ester used in the present invention is a monofatty acid ester having 10 to 26 carbon atoms of fatty acid from the viewpoint of low-temperature stability and feeling of use of rhododendrol or a derivative thereof. Even when a difatty acid ester of propylene glycol or a mono-C 8 fatty acid ester of propylene glycol is blended, an oil-in-water emulsion composition having good stability cannot be obtained. As the (B) propylene glycol mono C 10 -C 26 fatty acid ester, those represented by the following general formula (2) are preferable.
Figure JPOXMLDOC01-appb-C000005
Figure JPOXMLDOC01-appb-C000005
(式中、R2は、炭素数9~25の直鎖状又は分岐鎖状の、飽和又は不飽和の脂肪族炭化水素基を示す。) (In the formula, R 2 represents a linear or branched, saturated or unsaturated aliphatic hydrocarbon group having 9 to 25 carbon atoms.)
 本発明で用いる(B)成分のより好ましいものとしては、低温安定性及び使用感の点から、R2が炭素数11~23の直鎖状又は分岐鎖状の、飽和又は不飽和の脂肪族炭化水素基のものであり、具体的には、ラウリン酸プロピレングリコール、ミリスチン酸プロピレングリコール、パルミチン酸プロピレングリコール、ステアリン酸プロピレングリコール、イソステアリン酸プロピレングリコール、オレイン酸プロピレングリコール、リノール酸プロピレングリコール、リノレン酸プロピレングリコール、パルミトオレイン酸プロピレングリコール、ベヘン酸プロピレングリコール等が挙げられる。本発明においてはこれらの1種又は2種以上を組み合わせて適宜使用することができる。 The more preferable component (B) used in the present invention, a low temperature in view of stability and usability, a straight chain or branched chain of R 2 is a carbon number of 11-23, saturated or unsaturated aliphatic Specific examples of hydrocarbon groups include propylene glycol laurate, propylene glycol myristate, propylene glycol palmitate, propylene glycol stearate, propylene glycol isostearate, propylene glycol oleate, propylene glycol linoleate, linolenic acid Examples include propylene glycol, propylene glycol palmitooleate, and propylene glycol behenate. In this invention, these 1 type (s) or 2 or more types can be combined suitably and can be used suitably.
 本発明で用いる(B)成分は、公知の物質であり、例えば脂肪酸とプロピレングリコールのエステル化により容易に製造できる。また、一般に市販もされており、ラウリン酸プロピレングリコールとしては、太陽化学株式会社から販売されているサンソフト25BD、イソステアリン酸プロピレングリコールとしては、クローダ社より販売されているシスロールPGMIS、オレイン酸プロピレングリコールとしては、太陽化学株式会社から販売されているサンソフト25ODV、ベヘン酸プロピレングリコールとしては、Novenon社から販売されているSchercemol PGML Ester等が挙げることができる。 (B) component used by this invention is a well-known substance, for example, can manufacture easily by esterification of a fatty acid and propylene glycol. In addition, it is also commercially available, and as propylene glycol laurate, Sunsoft 25BD sold by Taiyo Kagaku Co., Ltd., as propylene glycol isostearate, cislol PGMIS, propylene glycol oleate sold by Croda. For example, Sunsoft 25 ODV sold by Taiyo Kagaku Co., Ltd. and propylene glycol behenate include Schercemol PGML Ester sold by Novenon.
 (B)成分の本発明の組成物中における含有量は、低温安定性、使用感、皮膚刺激性の点から、好ましくは0.05~30質量%であり、より好ましくは0.05~20質量%、さらに好ましくは0.05~15質量%、さらに好ましくは0.1~10質量%である。 The content of the component (B) in the composition of the present invention is preferably 0.05 to 30% by mass, more preferably 0.05 to 20% from the viewpoints of low-temperature stability, usability, and skin irritation. The mass is more preferably 0.05 to 15 mass%, still more preferably 0.1 to 10 mass%.
 本発明の(A)成分と(B)成分の含有質量比(A/B)は、使用感(べたつき感のなさ、肌なじみ)、皮膚刺激感の点から、0.1~10が好ましく、より好ましくは0.1~5であり、さらに好ましくは0.2~5であり、さらにより好ましくは0.2~3であり、さらに好ましくは0.5~5である。 The content mass ratio (A / B) of the component (A) and the component (B) of the present invention is preferably 0.1 to 10 from the viewpoint of feeling of use (no stickiness, familiar skin) and skin irritation. More preferably, it is from 0.1 to 5, more preferably from 0.2 to 5, even more preferably from 0.2 to 3, and even more preferably from 0.5 to 5.
 本発明に用いる(C)水膨潤性粘土鉱物は、水と混合することにより膨潤してゲルを形成する粘土鉱物であって、皮膚外用製剤に配合できる粘土鉱物であればいずれでもよく、モンモリロナイト、バイデライト、ノントロナイト、サポナイト、ヘクトライト、ソーコナイト、スチーブンサイト等のスメクタイト系粘土鉱物、タルク、マイカ等の粘土鉱物、ジケイ酸塩、アイラーアイト、マカタイト、マガジアイト、ケニヤアイト等の層状ケイ酸塩等を挙げることができ、これらは単独又は2種以上を併用して用いても良い。これら水膨潤性粘土鉱物は、分散体(例えばゾル又はゲル)又は懸濁液の形態で利用するのが好ましい。 The (C) water-swellable clay mineral used in the present invention is a clay mineral that swells when mixed with water to form a gel, and may be any clay mineral that can be blended in an external preparation for skin, montmorillonite, Smectite clay minerals such as beidellite, nontronite, saponite, hectorite, sauconite, stevensite, clay minerals such as talc and mica, layered silicates such as disilicate, Eilerite, macatite, magadiite, and Kenyaite. These may be used singly or in combination of two or more. These water-swellable clay minerals are preferably used in the form of a dispersion (for example, sol or gel) or a suspension.
 これらのうち、好ましくは、スメクタイト系粘土鉱物であり、結晶格子構造内にアルカリ金属又はアルカリ土類金属のイオンを有するものが挙げられる。これらのうち、より好ましいものは、ヘクトライト、モンモリロナイト、ノントロナイト、サポナイト、バイデライト、ソーコナイト及びこれらの混合物であり、特に好ましくはヘクトライト、モンモリロナイト、サポナイト及びこれらの混合物である。 Of these, smectite clay minerals are preferred, and those having alkali metal or alkaline earth metal ions in the crystal lattice structure can be mentioned. Of these, more preferred are hectorite, montmorillonite, nontronite, saponite, beidellite, soconite, and mixtures thereof, and particularly preferred are hectorite, montmorillonite, saponite, and mixtures thereof.
 これら(C)成分は一般に市販されており、モンモリロナイトを含有する製品としては、クニピアG、クニピアF(クニミネ工業社製)、ベントナイトW、ベンゲル(ホージュン社製);サポナイトを含有する製品としては、ビーガムT、ビーガムHV、ビーガムF、ビーガムK(バンダービルド社製);ヘクトライトを含有する製品としては、ベントンEW、ベントンLT(エレメンティスジャパン社製)、ヘクタブライトAW、ヘクタブライト200、ヘクタブライトEW(アメリカンコロイド社製)等を挙げることができる。 These components (C) are generally commercially available, and products containing montmorillonite include Kunipia G, Kunipia F (manufactured by Kunimine Industries), Bentonite W, Bengel (manufactured by Hojun Co.); Veegum T, Veegum HV, Veegum F, Veegum K (manufactured by Vanderbilt); as products containing hectorite, Benton EW, Benton LT (manufactured by Elementis Japan), Hectablite AW, Hectablite 200, Hectablite EW (manufactured by American Colloid) and the like can be mentioned.
 (C)成分の本発明組成物中における含有量は、低温安定性、使用感、皮膚刺激性の点から、0.01~10質量%、より好ましくは0.02~5質量%、さらに好ましくは0.05~5質量%、さらにより好ましくは0.05~2質量%、最も好ましくは0.1~3質量%である。 The content of the component (C) in the composition of the present invention is 0.01 to 10% by mass, more preferably 0.02 to 5% by mass, and still more preferably, from the viewpoint of low-temperature stability, usability, and skin irritation. Is from 0.05 to 5% by weight, even more preferably from 0.05 to 2% by weight, and most preferably from 0.1 to 3% by weight.
 本発明の(B)成分と(C)成分の含有質量比(B/C)は、安定性、使用感(べたつき感、肌なじみ)、皮膚刺激感の点から、0.03~35が好ましく、より好ましくは0.4~35、さらに好ましくは0.5~15であり、さらに好ましくは0.5~10であり、さらに好ましくは0.5~8であり、さらに好ましくは1~5である。 The content ratio (B / C) of the component (B) and the component (C) of the present invention is preferably 0.03 to 35 from the viewpoints of stability, feeling of use (stickiness, familiarity with skin) and skin irritation. More preferably, it is 0.4 to 35, more preferably 0.5 to 15, more preferably 0.5 to 10, still more preferably 0.5 to 8, and further preferably 1 to 5. is there.
 本発明では、使用感を調整するために、さらに(D)1価~3価アルコールを含有することができる。(D)成分の好ましい例としては、1価のアルコールとして、エタノール、プロパノール、イソプロパノール、ブチルアルコール等の炭素数1~4の1価アルコールが挙げられ、2価のアルコールとしてはプロピレングリコール、1,2-ペンタンジオール、1,3-ブチレングリコール、ジプロピレングリコール等の炭素数2~6の2価アルコールが挙げられ、また3価のアルコールとしてはグリセリン、イソプレングリコール等の炭素数3~6の3価アルコールが挙げられる。また、本発明では、これら1価~3価のアルコールから選択される1種又は2種以上を適宜組み合わせて用いることができる。 In the present invention, in order to adjust the feeling of use, (D) monohydric to trihydric alcohol can be further contained. Preferred examples of the component (D) include monohydric alcohols such as ethanol, propanol, isopropanol, butyl alcohol and the like, and monovalent alcohols such as ethanol, propanol, isopropanol, and butyl alcohol. Divalent alcohols include propylene glycol, 1, Examples of the dihydric alcohol having 2 to 6 carbon atoms such as 2-pentanediol, 1,3-butylene glycol, dipropylene glycol and the like, and examples of the trivalent alcohol include 3 to 6 carbon atoms such as glycerin and isoprene glycol. And monohydric alcohols. In the present invention, one or more selected from these monovalent to trivalent alcohols can be used in appropriate combination.
 特にこれらのうち、エタノール、ジプロピレングリコール、1,3-ブチレングリコール及びグリセリンからなる群から選択される1種又は2種以上が好ましく用いることができる。 Particularly, among these, one or more selected from the group consisting of ethanol, dipropylene glycol, 1,3-butylene glycol and glycerin can be preferably used.
 特許文献4に記載の皮膚外用剤においては、水中油型乳化組成物では(D)成分を10質量%程度含有させておかないと、低温安定性を保つことが困難であったが、本発明においては、(A)成分、(B)成分及び(C)成分を併用することで、同等以上の経時安定性を保持することが可能となった。そのため、(D)成分の本発明組成物中の含有量は、皮膚刺激感緩和、使用感(べたつき感、肌なじみ)の点から、10質量%以下とすることが可能であり、0.01~10質量%が好ましく、より好ましくは0.1~8質量%、さらに好ましくは0.5~6質量%である。 In the external preparation for skin described in Patent Document 4, it is difficult to maintain low temperature stability unless the oil-in-water emulsion composition contains about 10% by mass of component (D). In, the combined use of the component (A), the component (B), and the component (C) makes it possible to maintain equal or better stability over time. Therefore, the content of the component (D) in the composition of the present invention can be 10% by mass or less from the viewpoints of skin irritation mitigation and feeling of use (tackiness, familiarity with skin). Is preferably 10 to 10% by mass, more preferably 0.1 to 8% by mass, and still more preferably 0.5 to 6% by mass.
 さらに本発明の水中油型乳化組成物には、本発明の効果を損なわない範囲で、前記必須成分の他、通常、医薬品、医薬部外品、化粧品等に配合される他の成分、例えば油剤、保湿剤、増粘剤、防腐剤、pH調整剤、水、アルコール類、薬剤、紫外線吸収剤、紫外線散乱剤、色素、香料等を必要に応じて適宜配合することができる。 Furthermore, in the oil-in-water emulsion composition of the present invention, in addition to the above essential components, other components usually blended in pharmaceuticals, quasi-drugs, cosmetics and the like, for example, oil agents, within the range not impairing the effects of the present invention. , Moisturizers, thickeners, preservatives, pH adjusters, water, alcohols, drugs, ultraviolet absorbers, ultraviolet scattering agents, dyes, fragrances, and the like can be appropriately blended as necessary.
 本発明の水中油型乳化組成物の用途は任意であるが、化粧料、医薬品、医薬部外品等に好適に用いることができる。具体的には、ローション、乳液、美容クリーム、下地化粧料、日焼け止め化粧料、パック、マッサージ化粧料などの皮膚化粧料;各種薬剤を含有するクリーム等の外用医薬品として好適に利用できる。特に、本発明の水中油型乳化組成物は、べたつき感やぬるつき感がないため、皮膚化粧料として好適に利用できる。 Although the use of the oil-in-water emulsion composition of the present invention is arbitrary, it can be suitably used for cosmetics, pharmaceuticals, quasi drugs and the like. Specifically, skin cosmetics such as lotions, milky lotions, beauty creams, base cosmetics, sunscreen cosmetics, packs, massage cosmetics, etc .; can be suitably used as external medicines such as creams containing various drugs. In particular, the oil-in-water emulsion composition of the present invention does not have a sticky feeling or a slimy feeling, and therefore can be suitably used as a skin cosmetic.
 本発明の水中油型乳化組成物の剤形は任意であり、液状、エマルション、ジェル状、スプレー状、ムース状等のものとして調製される。 The dosage form of the oil-in-water emulsion composition of the present invention is arbitrary and is prepared as a liquid, emulsion, gel, spray, mousse or the like.
 以下に本発明及び好ましい実施態様の具体例を挙げる。 Specific examples of the present invention and preferred embodiments are given below.
<1>下記成分(A)~(C)を含有することを特徴とする水中油型乳化組成物。
(A)下記一般式(1)で示されるロドデンドロール又はその誘導体
<1> An oil-in-water emulsion composition comprising the following components (A) to (C):
(A) Rhodendrol or a derivative thereof represented by the following general formula (1)
Figure JPOXMLDOC01-appb-C000006
Figure JPOXMLDOC01-appb-C000006
(式中、R1は、水素原子、炭素数2~20のアシル基、又は単糖類若しくは二糖類の糖残基を示す。)
(B)プロピレングリコールモノC10~C26脂肪酸エステル
(C)水膨潤性粘土鉱物
<2>一般式(1)中のR1が、水素原子、炭素数2~20の飽和若しくは不飽和の脂肪族アシル基、又は単糖類若しくは二糖類の糖残基であり、好ましくは水素原子、炭素数2~18のアルカノイル基、又は単糖類若しくは二糖類の糖残基である、前記<1>の水中油型乳化組成物。
<3>一般式(1)中のR1が、好ましくは水素原子、炭素数2~8のアルカノイル基、又はグルコース、ガラクトース、キシロース、マンノース、N-アセチルグルコサミン、マルトース、セロビオース若しくはゲンタビオースの糖残基であり、より好ましくは水素原子、炭素数2~4のアルカノイル基、又はグルコース、ガラクトース、キシロース、マンノース、N-アセチルグルコサミンの糖残基である前記<1>又は<2>の水中油型乳化組成物。
<4>成分(A)の含有量が、0.5~20質量%、好ましくは0.5~15質量%、より好ましくは0.5~10質量%、さらに好ましくは0.5~5質量%である前記<1>~<3>のいずれかの水中油型乳化組成物。
<5>成分(B)が、一般式(2)
(In the formula, R 1 represents a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.)
(B) Propylene glycol mono C 10 -C 26 fatty acid ester (C) Water-swellable clay mineral <2> R 1 in the general formula (1) is a hydrogen atom, a saturated or unsaturated fat having 2 to 20 carbon atoms <1> in water, which is a group acyl group, or a sugar residue of a monosaccharide or a disaccharide, preferably a hydrogen atom, an alkanoyl group having 2 to 18 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide. Oil-type emulsion composition.
<3> R 1 in the general formula (1) is preferably a hydrogen atom, an alkanoyl group having 2 to 8 carbon atoms, or a sugar residue of glucose, galactose, xylose, mannose, N-acetylglucosamine, maltose, cellobiose or gentaviose. <1> or <2> of the oil-in-water type, more preferably a hydrogen atom, an alkanoyl group having 2 to 4 carbon atoms, or a sugar residue of glucose, galactose, xylose, mannose, N-acetylglucosamine Emulsified composition.
<4> The content of the component (A) is 0.5 to 20% by mass, preferably 0.5 to 15% by mass, more preferably 0.5 to 10% by mass, and further preferably 0.5 to 5% by mass. % Of the oil-in-water emulsion composition according to any one of <1> to <3>.
<5> The component (B) is represented by the general formula (2)
Figure JPOXMLDOC01-appb-C000007
Figure JPOXMLDOC01-appb-C000007
(式中、R2は、炭素数9~25の直鎖状又は分岐鎖状の、飽和又は不飽和の脂肪族炭化水素基を示す。)
で表されるものである前記<1>~<4>のいずれかの水中油型乳化組成物。
<6>成分(B)が、一般式(2)中のR2が、炭素数11~23の直鎖状又は分岐鎖状の、飽和又は不飽和の脂肪族炭化水素基である前記<5>の水中油型乳化組成物。
<7>成分(B)が、ラウリン酸プロピレングリコール、ミリスチン酸プロピレングリコール、パルミチン酸プロピレングリコール、ステアリン酸プロピレングリコール、イソステアリン酸プロピレングリコール、オレイン酸プロピレングリコール、リノール酸プロピレングリコール、リノレン酸プロピレングリコール、パルミトオレイン酸プロピレングリコール、及びベヘン酸プロピレングリコールからなる群から選択される1種又は2種以上である前記<1>~<6>のいずれかの水中油型乳化組成物。
<8>成分(B)の含有量が、0.05~30質量%、好ましくは0.05~20質量%、より好ましくは0.05~15質量%、さらに好ましくは0.1~10質量%、さらに好ましくは0.1~5質量%である前記<1>~<7>のいずれかの水中油型乳化組成物。
<9>成分(A)と成分(B)の含有質量比(A/B)が0.1~10、好ましくは0.1~5、より好ましくは0.2~5、さらに好ましくは0.2~3、さらに好ましくは0.5~5である前記<1>~<8>のいずれかの水中油型乳化組成物。
<10>成分(C)が、ヘクトライト、モンモリロナイト、ノントロナイト、サポナイト、バイデライト及びソーコナイトから選ばれる1種以上であり、好ましくはヘクトライト、モンモリロナイト及びサポナイトから選ばれる1種以上である<1>~<9>のいずれかの水中油型乳化組成物。
<11>成分(C)の含有量が、0.01~10質量%、好ましくは0.02~5質量%、さらに好ましくは0.05~5質量%、さらに好ましくは0.05~2質量%、さらに好ましくは0.1~3質量%である<1>~<10>のいずれかの水中油型乳化組成物。
<12>成分(B)と成分(C)の含有質量比(B/C)が、0.03~35、好ましくは0.4~35、より好ましくは0.5~15、さらに好ましくは0.5~10、さらに好ましくは0.5~8、さらに好ましくは1~5である<1>~<11>のいずれかの水中油型乳化組成物。
<13>さらに成分(D)1価~3価アルコールを含有する前記<1>~<12>のいずれかの水中油型乳化組成物。
<14>成分(D)が、炭素数1~4の1価アルコール、炭素数1~6の2価アルコール又は炭素数3~6の3価アルコールである前記<13>の水中油型乳化組成物。
<15>成分(D)の含有量が、0.01~10質量%、好ましくは0.1~8質量%、より好ましくは0.5~6質量%である前記<13>又は<14>の水中油型乳化組成物。
<16>前記成分(A)を含有する水中油型乳化組成物において、前記成分(B)及び成分(C)を含有させることによる水中油型乳化組成物の低温安定性の改善方法。
(In the formula, R 2 represents a linear or branched, saturated or unsaturated aliphatic hydrocarbon group having 9 to 25 carbon atoms.)
The oil-in-water emulsion composition according to any one of <1> to <4>, which is represented by:
<6> The component <B>, wherein R 2 in the general formula (2) is a linear or branched, saturated or unsaturated aliphatic hydrocarbon group having 11 to 23 carbon atoms <5 > An oil-in-water emulsion composition.
<7> Component (B) is propylene glycol laurate, propylene glycol myristate, propylene glycol palmitate, propylene glycol stearate, propylene glycol isostearate, propylene glycol oleate, propylene glycol linoleate, propylene glycol linolenate, palmitate The oil-in-water emulsion composition according to any one of <1> to <6>, wherein the emulsion composition is one or more selected from the group consisting of propylene glycol tooleate and propylene glycol behenate.
<8> The content of the component (B) is 0.05 to 30% by mass, preferably 0.05 to 20% by mass, more preferably 0.05 to 15% by mass, and further preferably 0.1 to 10% by mass. %, More preferably 0.1 to 5% by mass, the oil-in-water emulsion composition according to any one of <1> to <7>.
<9> The mass ratio (A / B) of the component (A) to the component (B) is 0.1 to 10, preferably 0.1 to 5, more preferably 0.2 to 5, and still more preferably 0.8. The oil-in-water emulsion composition according to any one of <1> to <8>, which is 2 to 3, more preferably 0.5 to 5.
<10> Component (C) is at least one selected from hectorite, montmorillonite, nontronite, saponite, beidellite and soconite, preferably at least one selected from hectorite, montmorillonite and saponite <1 The oil-in-water emulsion composition according to any one of> to <9>.
The content of <11> component (C) is 0.01 to 10% by mass, preferably 0.02 to 5% by mass, more preferably 0.05 to 5% by mass, and still more preferably 0.05 to 2% by mass. %, More preferably 0.1 to 3% by mass, the oil-in-water emulsion composition according to any one of <1> to <10>.
<12> The mass ratio (B / C) of the component (B) to the component (C) is 0.03 to 35, preferably 0.4 to 35, more preferably 0.5 to 15, and still more preferably 0. The oil-in-water emulsion composition according to any one of <1> to <11>, which is 5 to 10, more preferably 0.5 to 8, and more preferably 1 to 5.
<13> The oil-in-water emulsion composition according to any one of <1> to <12>, further comprising a component (D) a monohydric to trihydric alcohol.
<14> The oil-in-water emulsion composition according to <13>, wherein the component (D) is a monohydric alcohol having 1 to 4 carbon atoms, a dihydric alcohol having 1 to 6 carbon atoms, or a trihydric alcohol having 3 to 6 carbon atoms. object.
<15> The above <13> or <14>, wherein the content of the component (D) is 0.01 to 10% by mass, preferably 0.1 to 8% by mass, more preferably 0.5 to 6% by mass. An oil-in-water emulsion composition.
<16> A method for improving the low-temperature stability of an oil-in-water emulsion composition comprising the component (B) and the component (C) in the oil-in-water emulsion composition containing the component (A).
 次に本発明を実施例によりさらに詳細に説明するが、本発明はこれにより限定されるものではない。尚、以下に示す配合量は質量%である。実施例に先立ち、実施例において行った評価方法について説明する。 Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto. In addition, the compounding quantity shown below is the mass%. Prior to the examples, the evaluation methods performed in the examples will be described.
(安定性評価)
 室温(20±5℃)及び0℃で1ヶ月間保存した試料について、目視にて、試料中の結晶の析出有無を確認した。下記結晶析出判定基準に準じて評価を行った。
(Stability evaluation)
About the sample preserve | saved for one month at room temperature (20 +/- 5 degreeC) and 0 degreeC, the presence or absence of precipitation of the crystal | crystallization in a sample was confirmed visually. Evaluation was performed according to the following criteria for determining crystal precipitation.
結晶析出判定基準
 C:明らかな結晶の析出がある
 B:僅かに結晶の析出がある
 A:結晶の析出が見られない
Criteria for determining crystal precipitation C: Clear crystal precipitation B: Slight crystal precipitation A: No crystal precipitation
(皮膚刺激性評価)
 安定性評価により、明らかな結晶の析出が見られなかった0℃で1ヶ月保存した試料を、事前アンケートにより、敏感肌と自認している女性パネル(20~50代)10名により、試料を朝晩2回、3日間連続で使用し、最終日に以下の皮膚刺激性判定基準に従って、皮膚刺激性を判定した。なお、刺激感を感じた場合には使用を適宜中止してもらい、使用中止した時点で判定を行ってもらった。評価は、判定結果の平均点を算出することにより行った。尚、女性パネルには、1回にひとつの試料を評価し、2日間の休止期間を設けた後、同様にして次の試料を評価した。
(Skin irritation evaluation)
Samples stored for 1 month at 0 ° C, where no apparent crystal precipitation was observed by stability evaluation, were sampled by 10 female panels (20-50s) who were recognized as sensitive skin by a preliminary questionnaire. It was used twice a morning and evening for 3 consecutive days, and the skin irritation was determined according to the following criteria for skin irritation on the last day. In addition, when a feeling of irritation was felt, the use was stopped appropriately, and the determination was made when the use was stopped. Evaluation was performed by calculating the average score of the determination results. The female panel was evaluated one sample at a time, and after a 2-day rest period, the next sample was evaluated in the same manner.
皮膚刺激性判定基準
 4点:かなり刺激を感じる
 3点:刺激を感じる
 2点:やや刺激を感じる
 1点:ほとんど刺激を感じない
 0点:まったく刺激を感じない
Criteria for skin irritation 4 points: I feel quite irritation 3 points: I feel irritation 2 points: I feel some irritation 1 point: I hardly feel irritation 0 points: I don't feel irritation at all
(官能評価)
 安定性評価により、析出が見られなかった0℃で1ヶ月保存した試料を、専門評価パネラー10名により、試料を使用してもらい「べたつきのなさ」、「しっとり感」、「肌なじみの良さ」の各評価項目に関して、下記判定基準により官能評価を実施した。評価は、判定結果の平均点を算出することにより行った。尚、女性パネルには、1回にひとつの試料を評価し、2日間の休止期間を設けた後、同様にして次の試料を評価した。
(sensory evaluation)
Samples stored for 1 month at 0 ° C where no precipitation was observed by stability evaluation were used by 10 expert evaluation panelists to obtain samples that were not sticky, moist, and skin-friendly. The sensory evaluation was performed according to the following criteria for each evaluation item. Evaluation was performed by calculating the average score of the determination results. The female panel was evaluated one sample at a time, and after a 2-day rest period, the next sample was evaluated in the same manner.
判定基準
 5点:非常に良い。
 4点:良い。
 3点:普通。
 2点:やや悪い。
 1点:悪い。
Judgment criteria 5 points: Very good.
4 points: Good.
3 points: Normal.
2 points: Somewhat bad.
1 point: Bad.
実施例1~31、比較例1~8
 表1-1、1-2、表2に記載の処方により水中油型乳化組成物を作製し、前記評価試験を実施した。結果を表1-1、1-2、表2に併せて示す。
Examples 1-31 and Comparative Examples 1-8
Oil-in-water emulsion compositions were prepared according to the formulations shown in Table 1-1, 1-2, and Table 2, and the evaluation test was performed. The results are shown in Tables 1-1, 1-2, and Table 2.
Figure JPOXMLDOC01-appb-T000008
Figure JPOXMLDOC01-appb-T000008
Figure JPOXMLDOC01-appb-T000009
Figure JPOXMLDOC01-appb-T000009
Figure JPOXMLDOC01-appb-T000010
Figure JPOXMLDOC01-appb-T000010
(製造方法)
 A:成分1~9、15~19を混合して80℃に加熱し、攪拌混合する。
 B:成分10~13、21~22を混合して80℃に加熱し、攪拌混合する。
 C:AにBを徐々に徐々に添加し、均一に攪拌混合する。
 D:冷却後、Cに成分14を添加し、さらに均一に攪拌混合する。
(Production method)
A: Components 1 to 9 and 15 to 19 are mixed, heated to 80 ° C., and mixed with stirring.
B: Components 10 to 13 and 21 to 22 are mixed, heated to 80 ° C., and mixed with stirring.
C: B is gradually added to A and stirred and mixed uniformly.
D: After cooling, component 14 is added to C, and further stirred and mixed.
 表1-1、1-2及び表2より明らかなように、(B)成分を含有しない比較例1では室温及び低温安定性を保つことが出来なかった。(B)成分の代わりに炭素数が9未満のカプリル酸プロピレングリコールを用いた比較例2、5や、モノ体でないジカプリル酸プロピレングリコールを用いた比較例3、6も室温及び低温安定性を十分に保つことができなかった。また、(C)成分を含有しない比較例4、7、8では、析出は見られなかったが、べたつきのなさ、しっとり感、肌なじみの良さといった使用感において満足できるものでなかった。
 一方、本発明の実施例では、常温及び低温安定性に優れたものであった。析出が生じないことから、(A)成分の配合量が少なくても高い美白効果が得られることが期待される。また、皮膚刺激性、使用感も、(A)~(C)成分を併用することで、良い評価が得られた。
As is clear from Tables 1-1, 1-2 and Table 2, Comparative Example 1 containing no component (B) could not maintain room temperature and low temperature stability. (B) Comparative Examples 2 and 5 using propylene glycol caprylate having less than 9 carbon atoms instead of component, and Comparative Examples 3 and 6 using propylene glycol dicaprylate that is not a mono-body are also sufficient in room temperature and low temperature stability. Could not keep on. Further, in Comparative Examples 4, 7, and 8 containing no component (C), no precipitation was observed, but it was not satisfactory in terms of use such as non-stickiness, moist feeling, and good skin familiarity.
On the other hand, in the Example of this invention, it was excellent in normal temperature and low temperature stability. Since no precipitation occurs, it is expected that a high whitening effect can be obtained even if the amount of component (A) is small. In addition, the skin irritation and the feeling in use were evaluated well by using the components (A) to (C) in combination.
 次に、本発明の水中油型乳化組成物の処方例を示す。いずれも低温安定性に優れ、皮膚安全性が高く、美白効果・使用感に優れたものであることが期待される。 Next, formulation examples of the oil-in-water emulsion composition of the present invention will be shown. All are expected to have excellent low-temperature stability, high skin safety, and excellent whitening effect and feeling of use.
処方例1(乳液)
成分                        質量%
ロドデンドロール                  1.0
ロドデンドロール-D-ガラクトシド         4.0
イソステアリン酸プロピレングリコール
(商品名:シスロールPGMIS:クローダ社製)   1.0
モンモリロナイト                  0.4
ジプロピレングリコール               2.5
キサンタンガム                   0.03
ジメチコン                     0.5
1.3-ブチレングリコール             3.0
ステアリン酸                    0.4
モノステアリン酸グリセリン             1.2
ベヘニルアルコール                 0.1
コレステロール                   0.3
オレフィンオリゴマー                8.0
N-ステアロイル-L-グルタミン酸ナトリウム    0.5
カキョクエキス(商品名:火棘 サントリー社製)   0.1
ベルゲニアクラシホリア根エキス
(商品名:厚葉岩白菜抽出液BG 丸善製薬社製)    2.0
セイヨウニワトコ花エキス
(商品名:ニワトコ抽出液BG90 丸善製薬社製)  0.1
ホオノキ樹皮エキス
(商品名:ホオノキリキッドK 一丸ファルコス社製) 0.1
トウヒエキス
(商品名:トウヒリキッドB 一丸ファルコス社製)  0.1
ジュズダマエキス
(商品名:ヨクイニン抽出液BG-S 丸善製薬社製) 0.1
ピロ亜硫酸ナトリウム                0.02
エデト酸塩                     0.03
フェノキシエタノール                0.35
水                         残 量
Formulation Example 1 (Emulsion)
Ingredient Mass%
Rhododendrol 1.0
Rhododendrol-D-galactoside 4.0
Propylene glycol isostearate (trade name: Cisrol PGMIS: manufactured by Croda) 1.0
Montmorillonite 0.4
Dipropylene glycol 2.5
Xanthan gum 0.03
Dimethicone 0.5
1.3-Butylene glycol 3.0
Stearic acid 0.4
Glycerol monostearate 1.2
Behenyl alcohol 0.1
Cholesterol 0.3
Olefin oligomer 8.0
N-stearoyl-L-glutamate sodium 0.5
Oyster extract (trade name: Fire Thorn Suntory) 0.1
Bergenia Classifolia Root Extract (Trade name: Atsuba Iwanaka Extract BG, Maruzen Pharmaceutical Co., Ltd.) 2.0
Elderberry flower extract (trade name: Elderberry extract BG90, manufactured by Maruzen Pharmaceutical Co., Ltd.) 0.1
Honoki bark extract (trade name: Honoki Liquid K Ichimaru Falcos) 0.1
Spruce extract (trade name: Spruce Liquid B Ichimaru Falcos) 0.1
Juzudama extract (trade name: Yokuinin extract BG-S, manufactured by Maruzen Pharmaceutical Co., Ltd.) 0.1
Sodium pyrosulfite 0.02
Edetate 0.03
Phenoxyethanol 0.35
Residual amount of water
処方例2(乳液)
成分                        質量%
ロドデンドロール                  1.0
ブチロイルロドデンドロール             1.0
イソステアリン酸プロピレングリコール
(商品名:シスロールPGMIS:クローダ社製)    1.0
モンモリロナイト                  0.4
ジプロピレングリコール               3.5
キサンタンガム                   0.05
ジメチコン                     1.0
1.3-ブチレングリコール             3.0
ステアリン酸                    0.4
モノステアリン酸グリセリン             1.2
ベヘニルアルコール                 0.1
コレステロール                   0.3
オレフィンオリゴマー                8.0
N-ステアロイル-L-グルタミン酸ナトリウム    0.5
豆乳発酵液(商品名:豆乳発酵液 三省製薬社製)   0.1
オランダカラシ抽出物                0.1
(商品名:WaterCress-KB Silab社製)
ゲットウ葉抽出物                  0.1
(商品名:月桃葉抽出液BG 丸善製薬社製)
海藻抽出物(商品名:海藻エキスM 丸善製薬社製)  0.1
ピロ亜硫酸ナトリウム                0.02
エデト酸塩                     0.03
フェノキシエタノール                0.35
水                         残 量
Formulation example 2 (milky lotion)
Ingredient Mass%
Rhododendrol 1.0
Butyroyl rhododendrol 1.0
Propylene glycol isostearate (trade name: Cisrol PGMIS: manufactured by Croda) 1.0
Montmorillonite 0.4
Dipropylene glycol 3.5
Xanthan gum 0.05
Dimethicone 1.0
1.3-Butylene glycol 3.0
Stearic acid 0.4
Glycerol monostearate 1.2
Behenyl alcohol 0.1
Cholesterol 0.3
Olefin oligomer 8.0
N-stearoyl-L-glutamate sodium 0.5
Soymilk fermentation broth (trade name: Soymilk fermentation broth manufactured by Sansho Pharmaceutical Co., Ltd.) 0.1
Dutch mustard extract 0.1
(Product name: WaterCress-KB made by Silab)
Ghetto leaf extract 0.1
(Product name: Moon peach leaf extract BG manufactured by Maruzen Pharmaceutical Co., Ltd.)
Seaweed extract (trade name: Seaweed Extract M, manufactured by Maruzen Pharmaceutical Co., Ltd.) 0.1
Sodium pyrosulfite 0.02
Edetate 0.03
Phenoxyethanol 0.35
Residual amount of water

Claims (6)

  1.  下記成分(A)~(C)を含有することを特徴とする水中油型乳化組成物。
    (A)下記一般式(1)で示されるロドデンドロール又はその誘導体
    Figure JPOXMLDOC01-appb-C000001
    (式中、R1は、水素原子、炭素数2~20のアシル基、又は単糖類若しくは二糖類の糖残基を示す。)
    (B)プロピレングリコールモノC10~C26脂肪酸エステル
    (C)水膨潤性粘土鉱物
    An oil-in-water emulsion composition comprising the following components (A) to (C):
    (A) Rhodendrol or a derivative thereof represented by the following general formula (1)
    Figure JPOXMLDOC01-appb-C000001
    (In the formula, R 1 represents a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.)
    (B) Propylene glycol mono C 10 -C 26 fatty acid ester (C) Water-swellable clay mineral
  2. 成分(B)と成分(C)の含有質量比(B/C)が、0.03~35である請求項1に記載の水中油型乳化組成物。 The oil-in-water emulsion composition according to claim 1, wherein the content ratio (B / C) of component (B) to component (C) is 0.03 to 35.
  3.  さらに、(D)1価~3価アルコールを10質量%以下含有する請求項1又は2に記載の水中油型乳化組成物。 3. The oil-in-water emulsion composition according to claim 1 or 2, further comprising (D) 10% by mass or less of monohydric to trihydric alcohol.
  4.  前記(C)水膨潤性粘土鉱物が、モンモリロナイト、ヘクトライト、ボルコンスコイト、ノントロナイト、サポナイト、バイデライト及びソーコナイトからなる群から選択される1種以上である請求項1又は2に記載の水中油型乳化組成物。 3. The water according to claim 1, wherein the (C) water-swellable clay mineral is at least one selected from the group consisting of montmorillonite, hectorite, bolconskite, nontronite, saponite, beidellite and soconite. Oil-type emulsion composition.
  5.  皮膚化粧料である請求項1~4のいずれか1項に記載の水中油型乳化組成物。 The oil-in-water emulsion composition according to any one of claims 1 to 4, which is a skin cosmetic.
  6.  下記成分(A)を含有する水中油型乳化組成物において、成分(B)及び成分(C)を含有させることによる水中油型乳化組成物の低温安定性の改善方法。
    (A)下記一般式(1)で示されるロドデンドロール又はその誘導体
    Figure JPOXMLDOC01-appb-C000002
    (式中、R1は、水素原子、炭素数2~20のアシル基、又は単糖類若しくは二糖類の糖残基を示す。)
    (B)プロピレングリコールモノC10~C26脂肪酸エステル
    (C)水膨潤性粘土鉱物
    The oil-in-water emulsion composition containing the following component (A) WHEREIN: The improvement method of the low temperature stability of the oil-in-water emulsion composition by containing a component (B) and a component (C).
    (A) Rhodendrol or a derivative thereof represented by the following general formula (1)
    Figure JPOXMLDOC01-appb-C000002
    (In the formula, R 1 represents a hydrogen atom, an acyl group having 2 to 20 carbon atoms, or a sugar residue of a monosaccharide or a disaccharide.)
    (B) Propylene glycol mono C 10 -C 26 fatty acid ester (C) Water-swellable clay mineral
PCT/JP2012/059568 2011-04-08 2012-04-06 Oil-in-water emulsion composition WO2012137940A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011086672 2011-04-08
JP2011-086672 2011-04-08

Publications (1)

Publication Number Publication Date
WO2012137940A1 true WO2012137940A1 (en) 2012-10-11

Family

ID=46969328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/059568 WO2012137940A1 (en) 2011-04-08 2012-04-06 Oil-in-water emulsion composition

Country Status (3)

Country Link
JP (1) JP2012224624A (en)
TW (1) TW201244745A (en)
WO (1) WO2012137940A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266442A1 (en) * 2016-07-04 2018-01-10 Clariant International Ltd Emulsion stabilized by clay

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008031144A (en) * 2006-06-27 2008-02-14 Kao Corp Bleaching cosmetic
JP2008081491A (en) * 2006-09-01 2008-04-10 Kao Corp External preparation for skin
JP2008273851A (en) * 2007-04-26 2008-11-13 Kao Corp External preparation for skin
WO2009081587A1 (en) * 2007-12-25 2009-07-02 Kao Corporation External preparation for skin
JP2010111613A (en) * 2008-11-05 2010-05-20 Kao Corp Aqueous bleaching cosmetic
JP2010143848A (en) * 2008-12-18 2010-07-01 Kao Corp Cosmetic

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008031144A (en) * 2006-06-27 2008-02-14 Kao Corp Bleaching cosmetic
JP2008081491A (en) * 2006-09-01 2008-04-10 Kao Corp External preparation for skin
JP2008273851A (en) * 2007-04-26 2008-11-13 Kao Corp External preparation for skin
WO2009081587A1 (en) * 2007-12-25 2009-07-02 Kao Corporation External preparation for skin
JP2010111613A (en) * 2008-11-05 2010-05-20 Kao Corp Aqueous bleaching cosmetic
JP2010143848A (en) * 2008-12-18 2010-07-01 Kao Corp Cosmetic

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266442A1 (en) * 2016-07-04 2018-01-10 Clariant International Ltd Emulsion stabilized by clay
WO2018007261A1 (en) * 2016-07-04 2018-01-11 Clariant International Ltd Emulsion stabilized by clay

Also Published As

Publication number Publication date
JP2012224624A (en) 2012-11-15
TW201244745A (en) 2012-11-16

Similar Documents

Publication Publication Date Title
WO2009081587A1 (en) External preparation for skin
JP4563194B2 (en) Composition for external use
JP2008019230A5 (en)
JP3908969B2 (en) Cosmetics
JPH10167951A (en) Cosmetic
JP2012001458A (en) Skin care composition for external use
EP0911019A1 (en) Deodorizing compositions based on flavone derivatives and/or flavanone derivatives, especially flavonoids
JP6531514B2 (en) Emulsified composition
KR101361430B1 (en) Skin external preparation having excellent stability
WO2012137940A1 (en) Oil-in-water emulsion composition
JP4757718B2 (en) Skin preparation for strengthening skin barrier
WO2012137939A1 (en) Oil-in-water emulsion composition
JP4571514B2 (en) Vesicle external composition
JP4761852B2 (en) Topical skin preparation
JP2006199634A (en) Vesicle-based composition for external use
WO2012137938A1 (en) Oil-in-water emulsion composition
JP2010030933A (en) Skin care preparation for external use
JP2009132645A (en) Acylated hydroquinone glucoside and skin care preparation for external use comprising the same
JP5165860B2 (en) External preparation for skin containing 4-alkylresorcinol
JP4122272B2 (en) Cosmetics for treatment of lips roughening
DE10057770A1 (en) Cosmetic or dermatological composition comprises dispersed liquid crystals forming a cubic phase
JP2016172700A (en) Emulsion composition
JP6054175B2 (en) Skin external preparation for hair
JP2010030934A (en) Skin care preparation for external use
JP2014108944A (en) Skin external preparations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12767289

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12767289

Country of ref document: EP

Kind code of ref document: A1